1
However, the outcome of systemic chemotherapy has been disappointing in advanced HCC.
2
This study provides a compelling rationale for clinical investigation in patients with advanced HCC.
3
We then investigated the association between CD38 and ICB treatment outcomes in advanced HCC.
4
The echocardiography should be performed for patients with advanced HCC.
5
However, advanced HCC sees high heterogeneity across patient groups.
6
While sorafenib has a survival benefit for patients with advanced HCC, clinical response is highly variable.
7
The expression patterns in HCC were also readily distinguished between early and advanced HCC tumor stages.
8
Here, we report the experience with sorafenib in 25 patients with advanced HCC under daily practice conditions.
9
Conclusions: Long-term survival can be achieved using an aggressive surgical approach in select patients with advanced HCC.
10
Conclusions: There is evidence that SR may be a better viable option for advanced HCC with PVTT.
11
Conclusion: Well maintained liver function and performance status are prerequisites for sorafenib treatment in patients with advanced HCC.
12
Sorafenib was originally identified as an inhibitor of multiple oncogenic kinases and remains the only approved systemic therapy for advanced HCC.
13
However, a randomized phase III trial based on this regimen is warranted to clarify its survival benefit in patients with advanced HCC.
14
However, CLIP score has the highest stratification ability in patients with advanced HCC highlighting the importance of including AFP in best staging system.
15
Conclusion: A decrease in the congestion index revealed by DDU provides an early evaluation of response in patients taking sorafenib for advanced HCC.
16
Background & aims: Sorafenib has become the standard first-line treatment for patients with advanced HCC and acts by inducing alterations in tumor vascularity.
